

Knobbe Martens Olson & Bear LLP

Intellectual Property Law

2040 Main Street
Fourteenth Floor
Irvine, CA 92614
Tel 949-760-0404
Fax 949-760-9502
www.kmob.com

Che S. Chereskin
Patent Agent

July 15, 2010

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: Title: METHOD OF TREATING CANCER USING PLATELET RELEASEATE
Letters Patent No. 7,678,780
Issued: March 16, 2010
Our Reference: MISHRA.023NP

Dear Sir:

Enclosed for filing is a Certificate of Correction in connection with the above-identified patent.

As some of the errors cited in the Certificate of Correction were incurred through the fault of the Applicant, the required fee of \$100 will be paid via the EFS Web. Please charge any additional fees to our Deposit Account No. 11-1410.

Respectfully submitted,

Knobbe, Martens, Olson & Bear, LLP



Che Swyden Chereskin, Ph.D.
Registration No. 41,466
Customer No. 20995

Enclosures

9345927
071410

San Diego
619-235-8550

San Francisco
415-954-4114

Los Angeles
310-551-3450

Riverside
951-781-9231

Seattle
206-405-2000

Washington, DC
202-640-6400

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,678,780
APPLICATION NO. : 10/581,577
ISSUE DATE : March 16, 2010
INVENTOR(S) : Mishra, Allan

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Sheet 1 of Drawings (FIG. 1), Below X Axis, "Initial and 7 Day Counts" should be changed to

--Initial and 7 Day Counts--

Column 2, Line 42, "and mylosuppression," should be changed to --and myelosuppression,--

Column 4, Line 57, "as a minisule protoplasmic" should be changed to --as a minuscule protoplasmic--

Column 7, Line 58, "which have initially" should be changed to --interleukins which have initially--

Column 8, Line 2, "lumen of capilleries" should be changed to --lumen of capillaries--

Column 9, Line 18, "such as Fos, and Myc." should be changed to --such as Fos, Jun and Myc.--

Column 9, Line 60, "widley expressed in" should be changed to --widely expressed in--

Column 10, Lines 23-24, "foot anomalies" should be changed to --foot anomalies--

Column 10, Line 31, "Trasforming Growth Factors- β (TGFS- β) should be changed to

--Transforming Growth Factors- β (TGFS- β)--

Column 10, Line 46, "strength of of tissues" should be changed to --strength of tissues--

Column 11, Line 46, "growth of erythoid" should be changed to --growth of erythroid--

Column 12, Line 23, "The IL-1 is are" should be changed to --The IL1s are--

Column 13, Line 1, "Tumor Necrosos Factor- α (TNF- α)" should be changed to

--Tumor Necrosis Factor- α (TNF- α)--

Column 13, Line 35, "for IFN- γ 0 and" should be changed to --for IFN- γ and--

Column 14, Line 26, "cytolines or other" should be changed to --cytokines or other--

Column 14, Line 39, "that by taling tissue" should be changed to --that by taking tissue--

Column 16, Line 18, "human thombin." should be changed to --human thrombin...--

MAILING ADDRESS OF SENDER:

Che Swyden Chereskin, Ph.D.
KNOBBE, MARTENS, OLSON & BEAR, LLP
2040 Main Street, 14th Floor
Irvine, California 92614

DOCKET NO. MISHRA.023NP

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,678,780

Page 2 of 2

APPLICATION NO. : 10/581,577

ISSUE DATE : March 16, 2010

INVENTOR(S) : Mishra, Allan

Column 18, Line 60, "resulting in myelotoxicity," should be changed to --resulting in myelotoxicity,--

Column 18, Line 65, "platelet releasate may" should be changed to --platelet releasate may--

Column 19, Line 15, "and/or platelet releasate" should be changed to --and/or platelet releasate--

Column 19, Line 16, "prevention of autologous" should be changed to --prevention of autologous--

9345607
071410

MAILING ADDRESS OF SENDER:

Che Swyden Chereskin, Ph.D.
KNOBBE, MARTENS, OLSON & BEAR, LLP
2040 Main Street, 14th Floor
Irvine, California 92614

DOCKET NO. MISHRA.023NP